Elamipretide study reports fertility gains in aged mice

A study published October 2 in Aging Cell reports that elamipretide increased litter size in aged mice and improved human egg-cell development in laboratory experiments. The findings raise a reproductive-aging research question, but do not establish a treatment that improves pregnancy or live-birth outcomes in women.

The distinction matters because elamipretide already has an FDA-approved use. That regulatory history can inform future development, but evidence for one disease cannot establish effectiveness or safety for another purpose.

### What the researchers tested

The experiments compared treated aged mice with controls and examined egg maturation, fertilization and early embryo development. The reported mouse fertility benefit lasted only about one month.

In the human laboratory component, the paper reports 54 immature eggs from three women aged at least 35, allocated between treatment and control conditions. Resulting embryos were used for research, without clinical transfer. These are experiments on human cells, rather than a trial treating women for infertility.

That difference changes how the endpoints should be read. An egg reaching a developmental milestone is biologically informative. Establishing a clinical benefit would require evidence that an intervention improves outcomes meaningful to patients, while adequately assessing harms. Multiple eggs from one donor also cannot be treated as equivalent to evidence from multiple independent patients.

### What the existing approval establishes

The FDA granted accelerated approval to Forzinity, the elamipretide product, on September 19, 2025. Its indication is improvement of muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. The agency describes the drug as a mitochondrial cardiolipin binder.

The approval's supporting efficacy study enrolled 12 male patients with Barth syndrome. It included a randomized, blinded, placebo-controlled crossover phase and a subsequent open-label extension. The randomized portion did not demonstrate superiority over placebo on its primary measures of walking distance and fatigue.

The FDA says increases in knee-extensor muscle strength emerged during the longer open-label period. Accelerated approval allows access while confirmatory research continues. This history offers a concrete example of why an approval must be interpreted alongside its population, endpoints and remaining evidence requirements.

None of those Barth syndrome endpoints answers whether elamipretide helps someone conceive. Nor can an all-male efficacy study resolve reproductive treatment questions in women.

### Safety questions remain separate

The prescribing information states that there are no data from Forzinity use in pregnant women to evaluate drug-associated risks of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Animal reproduction studies described in the label did not identify adverse developmental outcomes at the tested exposures, but that does not establish safety in human pregnancy.

The label also identifies injection-site reactions and potentially serious hypersensitivity. Laboratory exposure of an egg and administration of a medicine to a person create different exposure conditions; their safety questions should not be merged.

For drug development, the next meaningful steps would include independent replication, more representative donor sampling and a clearly defined clinical research strategy. Pregnancy outcomes, offspring health and the durability of any benefit would need direct evaluation. The practical significance is a reason to investigate a candidate further, with clinical claims held to the outcomes that future studies actually measure.